Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.

Abstract

Back in 1982 the first biotech product, recombinant human insulin, hit the market. Hitherto, the biotechnology industry has largely been immune to generic competition with most firms still struggling to turn their ideas into products. The boom in generic pharmaceuticals has not included biotech medicines. The last five years however saw the biotech market growing at a compound annual growth rate CAGR of 27.7%. Patent protection on many biotech drugs is on the verge of expiry. By 2006, 11 biotech drugs worth more than US$13 billion in annual sales would face generic competition in America and the European Union. However hurdles remain in the form of the complexity of the biogeneric development process, regulatory barriers, and lobbying by patent holding companies. The case throws light on these opportunities and challenges facing generic companies. A structured assignment ''204-011-4'' is available to accompany this case.
Industry:
Other setting(s):
2003

About

Abstract

Back in 1982 the first biotech product, recombinant human insulin, hit the market. Hitherto, the biotechnology industry has largely been immune to generic competition with most firms still struggling to turn their ideas into products. The boom in generic pharmaceuticals has not included biotech medicines. The last five years however saw the biotech market growing at a compound annual growth rate CAGR of 27.7%. Patent protection on many biotech drugs is on the verge of expiry. By 2006, 11 biotech drugs worth more than US$13 billion in annual sales would face generic competition in America and the European Union. However hurdles remain in the form of the complexity of the biogeneric development process, regulatory barriers, and lobbying by patent holding companies. The case throws light on these opportunities and challenges facing generic companies. A structured assignment ''204-011-4'' is available to accompany this case.

Settings

Industry:
Other setting(s):
2003

Related